WO2007096382A3 - Ein verfahren zur herstellung einer transformierten zelle - Google Patents

Ein verfahren zur herstellung einer transformierten zelle Download PDF

Info

Publication number
WO2007096382A3
WO2007096382A3 PCT/EP2007/051661 EP2007051661W WO2007096382A3 WO 2007096382 A3 WO2007096382 A3 WO 2007096382A3 EP 2007051661 W EP2007051661 W EP 2007051661W WO 2007096382 A3 WO2007096382 A3 WO 2007096382A3
Authority
WO
WIPO (PCT)
Prior art keywords
biomolecule
cell
incorporation
complex
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/051661
Other languages
English (en)
French (fr)
Other versions
WO2007096382A2 (de
Inventor
Christoph Erbacher
Ute Krueger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qiagen GmbH
Original Assignee
Qiagen GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qiagen GmbH filed Critical Qiagen GmbH
Priority to AU2007217549A priority Critical patent/AU2007217549B2/en
Priority to JP2008555786A priority patent/JP5425477B2/ja
Priority to US12/280,499 priority patent/US8143229B2/en
Priority to CN2007800059291A priority patent/CN101384282B/zh
Priority to AT07712266T priority patent/ATE540699T1/de
Priority to EP07712266A priority patent/EP1986696B1/de
Publication of WO2007096382A2 publication Critical patent/WO2007096382A2/de
Publication of WO2007096382A3 publication Critical patent/WO2007096382A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/701—Integrated with dissimilar structures on a common substrate
    • Y10S977/702—Integrated with dissimilar structures on a common substrate having biological material component

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Die vorliegende Erfindung betrifft ein Verfahren zum Einschleusen eines Biomoleküls in eine Zelle, beinhaltend die Verfahrensschritte: i) Herstellen eines Komplexes aus einem Biomolekül, vorzugsweise einer Nukleinsäure, und einem Polymer, welches erhältlich ist durch Reaktion eines Amin-Monomers, aufweisend mindestens zwei Amin-Gruppen, mit einem Epoxid-Monomer, aufweisend mindestens zwei Epoxid-Gruppen, sowie ii) Einschleusen des Biomoleküls in eine Zelle durch das in Kontakt bringen einer Zelle mit dem Komplex. Die Erfindung betrifft auch die durch dieses Verfahren erhältliche, transformierte Zelle, die Verwendung eines bestimmten Polymers zum Einschleusen eines Biomoleküls in eine Zelle, einen Kit zum Einschleusen eines Biomoleküls in eine Zelle, die Verwendung dieses Kits, einen Komplex aus einem Biomolekül und einem Polymer, eine therapeutische Zusammensetzung, die Verwendung eines Komplexes aus einem Biomolekül und einem Polymer, ein Polymer zur therapeutischen Behandlung des menschlichen oder tierischen Körpers sowie ein Verfahren zur Behandlung einer Krankheit mittels Gentherapie.
PCT/EP2007/051661 2006-02-23 2007-02-21 Ein verfahren zur herstellung einer transformierten zelle Ceased WO2007096382A2 (de)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2007217549A AU2007217549B2 (en) 2006-02-23 2007-02-21 Method for production of a transformed cell
JP2008555786A JP5425477B2 (ja) 2006-02-23 2007-02-21 形質転換細胞の製造のための方法
US12/280,499 US8143229B2 (en) 2006-02-23 2007-02-21 Method for production of a transformed cell
CN2007800059291A CN101384282B (zh) 2006-02-23 2007-02-21 制备转化细胞的方法
AT07712266T ATE540699T1 (de) 2006-02-23 2007-02-21 Ein verfahren zur herstellung einer transformierten zelle
EP07712266A EP1986696B1 (de) 2006-02-23 2007-02-21 Ein verfahren zur herstellung einer transformierten zelle

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006008701A DE102006008701A1 (de) 2006-02-23 2006-02-23 Ein Verfahren zur Herstellung einer transformierten Zelle
DE102006008701.1 2006-02-23

Publications (2)

Publication Number Publication Date
WO2007096382A2 WO2007096382A2 (de) 2007-08-30
WO2007096382A3 true WO2007096382A3 (de) 2008-04-10

Family

ID=38038636

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/051661 Ceased WO2007096382A2 (de) 2006-02-23 2007-02-21 Ein verfahren zur herstellung einer transformierten zelle

Country Status (8)

Country Link
US (1) US8143229B2 (de)
EP (1) EP1986696B1 (de)
JP (1) JP5425477B2 (de)
CN (1) CN101384282B (de)
AT (1) ATE540699T1 (de)
AU (1) AU2007217549B2 (de)
DE (1) DE102006008701A1 (de)
WO (1) WO2007096382A2 (de)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078822A1 (en) * 2003-03-04 2004-09-16 Ebara Corporation Amine-cured type epoxy resin electrolyte having a sulfonic acid group and method for preparation thereof
EP1552818A1 (de) * 2004-01-07 2005-07-13 Shin-Etsu Chemical Co., Ltd. Zusammensetzung, die Freisetzung von Wirkstoffen verlängernd und Zubereitungen mit verlängerter Freisetzung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ512244A (en) * 1998-11-12 2003-12-19 Invitrogen Corp Polycationic transfection reagents for introducing anions into a cell
EP1163045B2 (de) * 1999-02-25 2007-08-22 Pall Corporation Positiv geladene membran
US20030215395A1 (en) * 2002-05-14 2003-11-20 Lei Yu Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
WO2005075527A1 (en) * 2004-01-30 2005-08-18 The General Hospital Corporation Hyperbranched polymers
US7985424B2 (en) * 2004-04-20 2011-07-26 Dendritic Nanotechnologies Inc. Dendritic polymers with enhanced amplification and interior functionality

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078822A1 (en) * 2003-03-04 2004-09-16 Ebara Corporation Amine-cured type epoxy resin electrolyte having a sulfonic acid group and method for preparation thereof
EP1552818A1 (de) * 2004-01-07 2005-07-13 Shin-Etsu Chemical Co., Ltd. Zusammensetzung, die Freisetzung von Wirkstoffen verlängernd und Zubereitungen mit verlängerter Freisetzung

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BANERJEE P. ET AL.: "Linear Polyethyleneimine Grafted to a Hyperbranched Poly(ethylene glycol)-like Core: A Copolymer for Gene Delivery", BIOCONJUGATE CHEMISTRY, vol. 17, 22 December 2005 (2005-12-22), pages 125 - 131, XP007904002 *
DATABASE CAPLUS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1999, QU R. ET AL.: "Adsorption property and mechanism of polymeric aza-crown ether resin for metallic ions", XP007904004 *
NGUYEN H K ET AL: "EVALUATION OF POLYETHER-POLYETHYLENEIMINE GRAFT COPOLYMERS AS GENE TRANSFER AGENTS", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 7, January 2000 (2000-01-01), pages 126 - 138, XP002947334, ISSN: 0969-7128 *
QU RONGJUN ET AL: "Adsorption property and mechanism of polymeric aza-crown ether resin for metallic ions", GAOFENZI CAILIAO KEXUE YU GONGCHENG, SICHUAN DAXUE, GAOFENZI YANJIUSUO,, CN, vol. 15, no. 2, May 1999 (1999-05-01), pages 151 - 154, XP008088326, ISSN: 1000-7555 *

Also Published As

Publication number Publication date
JP5425477B2 (ja) 2014-02-26
US20090010871A1 (en) 2009-01-08
CN101384282A (zh) 2009-03-11
AU2007217549A1 (en) 2007-08-30
EP1986696A2 (de) 2008-11-05
ATE540699T1 (de) 2012-01-15
US8143229B2 (en) 2012-03-27
DE102006008701A1 (de) 2007-08-30
CN101384282B (zh) 2013-03-20
EP1986696B1 (de) 2012-01-11
JP2009527239A (ja) 2009-07-30
WO2007096382A2 (de) 2007-08-30
AU2007217549B2 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
WO2008065372A3 (en) Modified erythropoietin polypeptides and uses thereof for treatment
WO2009044899A1 (ja) 細胞の増殖を制御する核酸
CA2796722C (en) Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types
EP2679246A3 (de) Neue therapeutische Mittel und Methoden um Blindheit zu behandeln
WO2011020783A3 (en) Targeted immunoconjugates
WO2011097181A3 (en) Compositions and methods for re-programming cells without genetic modification for treatment of neurological disorders
WO2007044727A3 (en) Pkr activation via hybridization chain reaction
WO2014186585A3 (en) Methods and compositions for treatment of a genetic condition
WO2012075040A3 (en) mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
WO2009026393A3 (en) Amino acid substituted molecules
NZ591137A (en) Methods and systems for predicting response of cells to a therapeutic agent
WO2007005180A3 (en) Method for enhancing engraftment of therapeutic cells at a target site
WO2008033413A3 (en) Albumin fusion proteins
WO2007146038A3 (en) Albumin fusion proteins
WO2008070672A3 (en) Compositions and methods to treat cancer with cupredoxins and cpg rich dna
NZ600376A (en) Elite event ee-gm3 and methods and kits for identifying such event in biological samples
WO2010025321A3 (en) Method for treating multiple sclerosis patients with anti-il2r antibodies
WO2006026485A3 (en) Modulation of hif1-beta expression
WO2008019052A3 (en) Methods and compositions for identifying biomarkers
WO2012056451A3 (en) Peripheral blood gene markers for early diagnosis of parkinson's disease
WO2008137881A3 (en) Ehrlichia ewingii proteins, nucleic acids, and methods of their use
WO2005071080A3 (en) Modulation of glucocorticoid receptor expression
WO2009111336A3 (en) Methods of purifying plasmid dna
EA201290107A1 (ru) Способ определения пациента как восприимчивого или не восприимчивого к иммунотерапии
WO2008011484A3 (en) Nicotinic desensitizers and methods of selecting, testing, and using them

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007217549

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2007217549

Country of ref document: AU

Date of ref document: 20070221

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2007217549

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200780005929.1

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 12280499

Country of ref document: US

Ref document number: 2008555786

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2007712266

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE